- Home
- MYGN vs TCBX Comparison
MYGN vs TCBX Comparison
Compare MYGN & TCBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TCBX
- Stock Information
- Founded
- MYGN 1991
- TCBX 2008
- Country
- MYGN United States
- TCBX United States
- Employees
- MYGN N/A
- TCBX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TCBX Banks
- Sector
- MYGN Health Care
- TCBX Finance
- Exchange
- MYGN Nasdaq
- TCBX Nasdaq
- Market Cap
- MYGN 423.1M
- TCBX 481.8M
- IPO Year
- MYGN 1995
- TCBX 2021
- Fundamental
- Price
- MYGN $7.64
- TCBX $39.34
- Analyst Decision
- MYGN Hold
- TCBX Hold
- Analyst Count
- MYGN 13
- TCBX 4
- Target Price
- MYGN $13.50
- TCBX $39.00
- AVG Volume (30 Days)
- MYGN 1.4M
- TCBX 57.9K
- Earning Date
- MYGN 11-06-2025
- TCBX 10-22-2025
- Dividend Yield
- MYGN N/A
- TCBX N/A
- EPS Growth
- MYGN N/A
- TCBX 52.43
- EPS
- MYGN N/A
- TCBX 3.28
- Revenue
- MYGN $832,900,000.00
- TCBX $182,318,000.00
- Revenue This Year
- MYGN $0.17
- TCBX $23.66
- Revenue Next Year
- MYGN $6.19
- TCBX $6.46
- P/E Ratio
- MYGN N/A
- TCBX $12.10
- Revenue Growth
- MYGN 3.83
- TCBX 20.25
- 52 Week Low
- MYGN $3.76
- TCBX $24.87
- 52 Week High
- MYGN $29.30
- TCBX $41.25
- Technical
- Relative Strength Index (RSI)
- MYGN 75.45
- TCBX 54.38
- Support Level
- MYGN $6.73
- TCBX $39.08
- Resistance Level
- MYGN $7.05
- TCBX $40.02
- Average True Range (ATR)
- MYGN 0.38
- TCBX 0.90
- MACD
- MYGN 0.10
- TCBX -0.18
- Stochastic Oscillator
- MYGN 94.31
- TCBX 17.83
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.